PO-S01 vs PO-S02

PO-S01 is a synthetic GLP-1 receptor mono-agonist with strategic amino acid substitutions and fatty acid acylation that extend its half-life to approximately 7 days in study models. As one of the most extensively studied incretin analogs, it serves as a benchmark compound for GLP-1 receptor research, with effects documented in glucose-dependent insulin secretion, appetite-regulatory circuits, and metabolic signaling cascades. PO-S02 is a synthetic peptide engineered to act as a dual agonist at both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. By engaging two incretin pathways simultaneously, po-s02 produces broader metabolic effects than mono-agonist compounds. Preclinical research has documented synergistic effects on energy expenditure, lipid metabolism, and body composition that are not achievable with GLP-1 stimulation alone.

PO-S01

Receptor Target GLP-1 only (mono-agonist)
Half-Life Profile ~7 days in study models
Research Maturity Extensively published; benchmark compound
Mechanism Breadth Single-pathway incretin
Primary Research Context Appetite, glucose homeostasis
Format Pre-measured research kit

PO-S02

Receptor Target GLP-1 + GIP (dual agonist)
Half-Life Profile ~5 days in study models
Research Maturity Strong literature; dual-agonist class leader
Mechanism Breadth Dual incretin pathway engagement
Primary Research Context Energy expenditure, lipid metabolism, body composition
Format Pre-measured research kit

The Verdict

PO-S01 and po-s02 represent two generations of incretin research. PO-S01 is the established GLP-1 mono-agonist with a deep body of published literature, making it the benchmark for GLP-1 receptor studies. PO-S02 adds GIP receptor engagement, allowing researchers to study coordinated dual-pathway effects on metabolism that mono-agonists cannot replicate. The choice depends on whether the research question requires isolated GLP-1 signaling or combined GLP-1/GIP modulation.

Explore These Products

PO-S01

A complete 10-vial po-s01 of lyophilized peptide. COA available. For research use only.

View Details →

PO-S02

A po-s02 packaged as a plastic box containing 10 lyophilized vials in the selected strength.

View Details →

PO-S01 vs PO-S02 — FAQ

How does po-s02 differ from po-s01?
PO-S01 activates only the GLP-1 receptor, while po-s02 simultaneously engages both GLP-1 and GIP receptors. This dual mechanism produces broader metabolic effects in preclinical models.
Which has more published research?
PO-S01 has substantially more published preclinical and in-vitro data and is widely considered a benchmark GLP-1 compound. PO-S02 has a smaller but rapidly growing body of literature.
Can they be compared head-to-head in research?
Yes. Comparative study designs are common in incretin research to isolate the contribution of GIP receptor engagement on metabolic outcomes.
What is the regulatory status?
Both kits sold through this platform are research-use-only and intended exclusively for in-vitro and preclinical study models.

References

Primary sources for key clinical and regulatory claims on this page.

  1. PO-S01, reduction in glycated haemoglobin and the risk of diabetic retinopathy — PubMed / Lancet Metabolic Disease Endocrinol . Key source establishing po-s01 as a benchmark GLP-1 receptor agonist in metabolic research models.
  2. PO-S02, a dual GIP and GLP-1 receptor agonist — PubMed / Nat Rev Endocrinol . Foundational reference for po-s02 dual-agonist pharmacology and metabolic effects.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Kits CategoryGLP-1 Pricing Guide
Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now